WNT signaling and distant metastasis in colon cancer through transcriptional activity of nuclear β-Catenin depend on active PI3K signaling

Oncotarget

Volumn 5, Issue 10, 2014, Pages 2999-3011

  Ormanns, Steffen ^a   Neumann, Jens ^a   Horst, David ^a   Kirchner, Thomas ^a,b   Jung, Andreas ^a,b  

^a UNIVERSITY OF MUNICH   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

B Catenin; Colon cancer; Metastasis; PI3K; WNT

Indexed keywords

BETA CATENIN; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; SERINE; CTNNB1 PROTEIN, HUMAN; PIK3CA PROTEIN, HUMAN;

ARTICLE; CANCER GROWTH; CELLULAR DISTRIBUTION; COLON CANCER; CONTROLLED STUDY; CORRELATIONAL STUDY; DISTANT METASTASIS; GENE; GENE EXPRESSION; GENE MUTATION; GENE TARGETING; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; IN VIVO STUDY; P13K SIGNALING PATHWAY; PIK3CA GENE; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REPORTER GENE ASSAY; SIGNAL TRANSDUCTION; TRANSACTIVATION ASSAY; TRANSCRIPTION INITIATION; TRANSCRIPTION REGULATION; WNT SIGNALING PATHWAY; BIOSYNTHESIS; CELL NUCLEUS; CHROMATIN IMMUNOPRECIPITATION; COLON TUMOR; FLUORESCENCE MICROSCOPY; GENE EXPRESSION REGULATION; GENETICS; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; METABOLISM; METASTASIS; NUCLEOTIDE SEQUENCE; PATHOLOGY; PHYSIOLOGY; POLYMERASE CHAIN REACTION; TUMOR CELL LINE; TUMOR INVASION;

BETA CATENIN; CELL LINE, TUMOR; CELL NUCLEUS; CHROMATIN IMMUNOPRECIPITATION; COLONIC NEOPLASMS; DNA MUTATIONAL ANALYSIS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; MICROSCOPY, FLUORESCENCE; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; PHOSPHATIDYLINOSITOL 3-KINASES; POLYMERASE CHAIN REACTION; TRANSCRIPTIONAL ACTIVATION; WNT SIGNALING PATHWAY;

EID: 84902120404     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.1626     Document Type: Article

References (57)

1. Siegel R, Naishadham D and Jemal A. Cancer statistics, 2013. CA: a cancer journal for clinicians. 2013; 63(1):11-30.
2. Mina LA and Sledge GW, Jr. Rethinking the metastatic cascade as a therapeutic target. Nature reviews Clinical oncology. 2011; 8(6):325-332.
3. Cancer Genome Atlas N. Comprehensive molecular characterization of human colon and rectal cancer. Nature. 2012; 487(7407):330-337.
4. Hanahan D and Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011; 144(5):646-674.
5. Thiery JP. Epithelial-mesenchymal transitions in development and pathologies. Current opinion in cell biology. 2003; 15(6):740-746.
6. Brabletz T, Jung A, Reu S, Porzner M, Hlubek F, Kunz-Schughart LA, Knuechel R and Kirchner T. Variable beta-catenin expression in colorectal cancers indicates tumor progression driven by the tumor environment. Proceedings of the National Academy of Sciences of the United States of America. 2001; 98(18):10356-10361.
7. Hlubek F, Brabletz T, Budczies J, Pfeiffer S, Jung A and Kirchner T. Heterogeneous expression of Wnt/beta-catenin target genes within colorectal cancer. International journal of cancer Journal international du cancer. 2007; 121(9):1941-1948.
8. Fodde R and Tomlinson I. Nuclear beta-catenin expression and Wnt signalling: in defence of the dogma. The Journal of pathology. 2010; 221(3):239-241.
9. Vermeulen L, De Sousa EMF, van der Heijden M, Cameron K, de Jong JH, Borovski T, Tuynman JB, Todaro M, Merz C, Rodermond H, Sprick MR, Kemper K, Richel DJ, Stassi G and Medema JP. Wnt activity defines colon cancer stem cells and is regulated by the microenvironment. Nature cell biology. 2010; 12(5):468-476.
10. Phelps RA, Chidester S, Dehghanizadeh S, Phelps J, Sandoval IT, Rai K, Broadbent T, Sarkar S, Burt RW and Jones DA. A two-step model for colon adenoma initiation and progression caused by APC loss. Cell. 2009; 137(4):623-634.
11. Horst D, Chen J, Morikawa T, Ogino S, Kirchner T and Shivdasani RA. Differential WNT activity in colorectal cancer confers limited tumorigenic potential and is regulated by MAPK signaling. Cancer research. 2012; 72(6):1547-1556.
12. Janssen KP, Alberici P, Fsihi H, Gaspar C, Breukel C, Franken P, Rosty C, Abal M, El Marjou F, Smits R, Louvard D, Fodde R and Robine S. APC and oncogenic KRAS are synergistic in enhancing Wnt signaling in intestinal tumor formation and progression. Gastroenterology. 2006; 131(4):1096-1109.
13. Vivanco I and Sawyers CL. The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nature reviews Cancer. 2002; 2(7):489-501.
14. Samuels Y, Wang Z, Bardelli A, Silliman N, Ptak J, Szabo S, Yan H, Gazdar A, Powell SM, Riggins GJ, Willson JK, Markowitz S, Kinzler KW, Vogelstein B and Velculescu VE. High frequency of mutations of the PIK3CA gene in human cancers. Science. 2004; 304(5670):554.
15. Fang D, Hawke D, Zheng Y, Xia Y, Meisenhelder J, Nika H, Mills GB, Kobayashi R, Hunter T and Lu Z. Phosphorylation of beta-catenin by AKT promotes beta-catenin transcriptional activity. The Journal of biological chemistry. 2007; 282(15):11221-11229.
16. Wu X, Tu X, Joeng KS, Hilton MJ, Williams DA and Long F. Rac1 activation controls nuclear localization of beta-catenin during canonical Wnt signaling. Cell. 2008; 133(2):340-353.
17. Baryawno N, Sveinbjornsson B, Eksborg S, Chen CS, Kogner P and Johnsen JI. Small-molecule inhibitors of phosphatidylinositol 3-kinase/Akt signaling inhibit Wnt/beta-catenin pathway cross-talk and suppress medulloblastoma growth. Cancer research. 2010; 70(1):266-276.
18. Stambolic V, Ruel L and Woodgett JR. Lithium inhibits glycogen synthase kinase-3 activity and mimics wingless signalling in intact cells. Current biology: CB. 1996; 6(12):1664-1668.
19. Shibamoto S, Higano K, Takada R, Ito F, Takeichi M and Takada S. Cytoskeletal reorganization by soluble Wnt-3a protein signalling. Genes to cells: devoted to molecular & cellular mechanisms. 1998; 3(10):659-670.
20. Vlahos CJ, Matter WF, Hui KY and Brown RF. A specific inhibitor of phosphatidylinositol 3-kinase, 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002). The Journal of biological chemistry. 1994; 269(7):5241-5248.
21. Nishisho I, Nakamura Y, Miyoshi Y, Miki Y, Ando H, Horii A, Koyama K, Utsunomiya J, Baba S and Hedge P. Mutations of chromosome 5q21 genes in FAP and colorectal cancer patients. Science. 1991; 253(5020):665-669.
22. Pujal J, Capella G and Real FX. The Wnt pathway is active in a small subset of pancreas cancer cell lines. Biochimica et biophysica acta. 2006; 1762(1):73-79.
23. He TC, Sparks AB, Rago C, Hermeking H, Zawel L, da Costa LT, Morin PJ, Vogelstein B and Kinzler KW. Identification of c-MYC as a target of the APC pathway. Science. 1998; 281(5382):1509-1512.
24. Shtutman M, Zhurinsky J, Simcha I, Albanese C, D'Amico M, Pestell R and Ben-Ze'ev A. The cyclin D1 gene is a target of the beta-catenin/LEF-1 pathway. Proceedings of the National Academy of Sciences of the United States of America. 1999; 96(10):5522-5527.
25. Hovanes K, Li TW, Munguia JE, Truong T, Milovanovic T, Lawrence Marsh J, Holcombe RF and Waterman ML. Beta-catenin-sensitive isoforms of lymphoid enhancer factor-1 are selectively expressed in colon cancer. Nature genetics. 2001; 28(1):53-57.
26. Davies SP, Reddy H, Caivano M and Cohen P. Specificity and mechanism of action of some commonly used protein kinase inhibitors. The Biochemical journal. 2000; 351(Pt 1):95-105.
27. Ji H, Wang J, Nika H, Hawke D, Keezer S, Ge Q, Fang B, Fang X, Fang D, Litchfield DW, Aldape K and Lu Z. EGF-induced ERK activation promotes CK2-mediated disassociation of alpha-Catenin from beta-Catenin and transactivation of beta-Catenin. Molecular cell. 2009; 36(4):547-559.
28. Miyata Y and Nishida E. Evaluating CK2 activity with the antibody specific for the CK2-phosphorylated form of a kinase-targeting cochaperone Cdc37. Molecular and cellular biochemistry. 2008; 316(1-2):127-134.
29. Sarno S, Reddy H, Meggio F, Ruzzene M, Davies SP, Donella-Deana A, Shugar D and Pinna LA. Selectivity of 4,5,6,7-tetrabromobenzotriazole, an ATP site-directed inhibitor of protein kinase CK2 ('casein kinase-2'). FEBS letters. 2001; 496(1):44-48.
30. Littlewood TD, Hancock DC, Danielian PS, Parker MG and Evan GI. A modified oestrogen receptor ligand-binding domain as an improved switch for the regulation of heterologous proteins. Nucleic acids research. 1995; 23(10):1686-1690.
31. Neumann J, Horst D, Kriegl L, Maatz S, Engel J, Jung A and Kirchner T. A simple immunohistochemical algorithm predicts the risk of distant metastases in right-sided colon cancer. Histopathology. 2012; 60(3):416-426.
32. Stambolic V, Suzuki A, de la Pompa JL, Brothers GM, Mirtsos C, Sasaki T, Ruland J, Penninger JM, Siderovski DP and Mak TW. Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN. Cell. 1998; 95(1):29-39.
33. Gera JF, Mellinghoff IK, Shi Y, Rettig MB, Tran C, Hsu JH, Sawyers CL and Lichtenstein AK. AKT activity determines sensitivity to mammalian target of rapamycin (mTOR) inhibitors by regulating cyclin D1 and c-myc expression. The Journal of biological chemistry. 2004; 279(4):2737-2746.
34. Filali M, Cheng N, Abbott D, Leontiev V and Engelhardt JF. Wnt-3A/beta-catenin signaling induces transcription from the LEF-1 promoter. The Journal of biological chemistry. 2002; 277(36):33398-33410.
35. Persad S, Troussard AA, McPhee TR, Mulholland DJ and Dedhar S. Tumor suppressor PTEN inhibits nuclear accumulation of beta-catenin and T cell/lymphoid enhancer factor 1-mediated transcriptional activation. The Journal of cell biology. 2001; 153(6):1161-1174.
36. Marsh V, Winton DJ, Williams GT, Dubois N, Trumpp A, Sansom OJ and Clarke AR. Epithelial Pten is dispensable for intestinal homeostasis but suppresses adenoma development and progression after Apc mutation. Nature genetics. 2008; 40(12):1436-1444.
37. Perry JM, He XC, Sugimura R, Grindley JC, Haug JS, Ding S and Li L. Cooperation between both Wnt/{beta}-catenin and PTEN/PI3K/Akt signaling promotes primitive hematopoietic stem cell self-renewal and expansion. Genes & development. 2011; 25(18):1928-1942.
38. Brown JB, Cheresh P, Goretsky T, Managlia E, Grimm GR, Ryu H, Zadeh M, Dirisina R and Barrett TA. Epithelial phosphatidylinositol-3-kinase signaling is required for beta-catenin activation and host defense against Citrobacter rodentium infection. Infection and immunity. 2011; 79(5):1863-1872.
39. Valenta T, Hausmann G and Basler K. The many faces and functions of beta-catenin. The EMBO journal. 2012; 31(12):2714-2736.
40. Clevers H and Nusse R. Wnt/beta-catenin signaling and disease. Cell. 2012; 149(6):1192-1205.
41. Reya T and Clevers H. Wnt signalling in stem cells and cancer. Nature. 2005; 434(7035):843-850.
42. Horst D, Kriegl L, Engel J, Kirchner T and Jung A. CD133 expression is an independent prognostic marker for low survival in colorectal cancer. British journal of cancer. 2008; 99(8):1285-1289.
43. Brabletz T, Hlubek F, Spaderna S, Schmalhofer O, Hiendlmeyer E, Jung A and Kirchner T. Invasion and metastasis in colorectal cancer: epithelial-mesenchymal transition, mesenchymal-epithelial transition, stem cells and beta-catenin. Cells, tissues, organs. 2005; 179(1-2):56-65.
44. Samuels Y, Diaz LA, Jr., Schmidt-Kittler O, Cummins JM, Delong L, Cheong I, Rago C, Huso DL, Lengauer C, Kinzler KW, Vogelstein B and Velculescu VE. Mutant PIK3CA promotes cell growth and invasion of human cancer cells. Cancer cell. 2005; 7(6):561-573.
45. Zhang J, Roberts TM and Shivdasani RA. Targeting PI3K signaling as a therapeutic approach for colorectal cancer. Gastroenterology. 2011; 141(1):50-61.
46. Tenbaum SP, Ordonez-Moran P, Puig I, Chicote I, Arques O, Landolfi S, Fernandez Y, Herance JR, Gispert JD, Mendizabal L, Aguilar S, Ramon y Cajal S, Schwartz S, Jr., Vivancos A, Espin E, Rojas S, et al. beta-catenin confers resistance to PI3K and AKT inhibitors and subverts FOXO3a to promote metastasis in colon cancer. Nature medicine. 2012; 18(6):892-901.
47. Schmidt-Kittler O, Zhu J, Yang J, Liu G, Hendricks W, Lengauer C, Gabelli SB, Kinzler KW, Vogelstein B, Huso DL and Zhou S. PI3Kalpha inhibitors that inhibit metastasis. Oncotarget. 2010; 1(5):339-348.
48. Guo XN, Rajput A, Rose R, Hauser J, Beko A, Kuropatwinski K, LeVea C, Hoffman RM, Brattain MG and Wang J. Mutant PIK3CA-bearing colon cancer cells display increased metastasis in an orthotopic model. Cancer research. 2007; 67(12):5851-5858.
49. Gulhati P, Bowen KA, Liu J, Stevens PD, Rychahou PG, Chen M, Lee EY, Weiss HL, O'Connor KL, Gao T and Evers BM. mTORC1 and mTORC2 regulate EMT, motility, and metastasis of colorectal cancer via RhoA and Rac1 signaling pathways. Cancer research. 2011; 71(9):3246-3256.
50. Rychahou PG, Kang J, Gulhati P, Doan HQ, Chen LA, Xiao SY, Chung DH and Evers BM. Akt2 overexpression plays a critical role in the establishment of colorectal cancer metastasis. Proceedings of the National Academy of Sciences of the United States of America. 2008; 105(51):20315-20320.
51. Rychahou PG, Jackson LN, Silva SR, Rajaraman S and Evers BM. Targeted molecular therapy of the PI3K pathway: therapeutic significance of PI3K subunit targeting in colorectal carcinoma. Annals of surgery. 2006; 243(6):833-842; discussion 843-834.
52. Ericson K, Gan C, Cheong I, Rago C, Samuels Y, Velculescu VE, Kinzler KW, Huso DL, Vogelstein B and Papadopoulos N. Genetic inactivation of AKT1, AKT2, and PDPK1 in human colorectal cancer cells clarifies their roles in tumor growth regulation. Proceedings of the National Academy of Sciences of the United States of America. 2010; 107(6):2598-2603.
53. Horton RM. PCR-mediated recombination and mutagenesis. SOEing together tailor-made genes. Molecular biotechnology. 1995; 3(2):93-99.
54. Liffers ST, Maghnouj A, Munding JB, Jackstadt R, Herbrand U, Schulenborg T, Marcus K, Klein-Scory S, Schmiegel W, Schwarte-Waldhoff I, Meyer HE, Stuhler K and Hahn SA. Keratin 23, a novel DPC4/Smad4 target gene which binds 14-3-3epsilon. BMC cancer. 2011; 11:137.
55. Hahn S, Jackstadt R, Siemens H, Hunten S and Hermeking H. SNAIL and miR-34a feed-forward regulation of ZNF281/ZBP99 promotes epithelial-mesenchymal transition. The EMBO journal. 2013; 32(23):3079-3095.
56. Neumann J, Wehweck L, Maatz S, Engel J, Kirchner T and Jung A. Alterations in the EGFR pathway coincide in colorectal cancer and impact on prognosis. Virchows Archiv: an international journal of pathology. 2013; 463(4):509-523.
57. Loupakis F, Pollina L, Stasi I, Ruzzo A, Scartozzi M, Santini D, Masi G, Graziano F, Cremolini C, Rulli E, Canestrari E, Funel N, Schiavon G, Petrini I, Magnani M, Tonini G, et al. PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2009; 27(16):2622-2629.